In the context of bone regeneration, CRISPR technology has demonstrated efficacy in activating osteogenic transcription factors such as RUNX2, OSX, and BMP‐2 and in suppressing osteoclast‐related genes such as RANK and NFATc1 to reduce bone resorption.[174, 175, 176, 177] Furthermore, CRISPR has also been investigated as a strategy to correct monogenic bone disorders such as osteogenesis imperfecta.[178]. This evidence concerns the gene RUNX2 and osteogenesis imperfecta.